Page last updated: 2024-12-11

tri-cyclen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9571023
SCHEMBL ID6382955
MeSH IDM0283176

Synonyms (37)

Synonym
ortho cyclen-28
ortho tri-cyclen
ortho cyclen-21
tri-sprintec
tricileste
norgestimate, ethinyl estradiol drug combination
pramino
ethinylestradiol-norgestimate mixt
estarylla
ortho tri-cyclen 28
norgestimate-ethinylestradiol mixt
tri-lo-sprintec
ortho cylen
tri-mili
trinessa
ortho tri lo
ortho tri cyclen
tri-linyah
mono-linyah
mili
ortho tri-cyclen lo
norgestimate and ethinyl estradiol
tri-estarylla
tri cyclen
mononessa
tri-lo-estarylla
ortho tri-cylen
79871-54-8
tri prevofem
norgestimate / ethinyl estradiol
ortho tri-cyclen 21
ethinyl estradiol and norgestimate
trinessa-28
18,19-dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime, (17alpha)-, mixt. with (17alpha)-19 norpregna-1,3,5(10)-trien-20-yne-3,17-diol
tricilest
SCHEMBL6382955
[(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" This analysis revealed that the OC exhibited a side effect profile that was similar, in many cases, to that of placebo."( Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence.
Godwin, AJ; Lippman, JS; Olson, W; Redmond, G, 1999
)
0.3

Pharmacokinetics

ExcerptReferenceRelevance
" Comparable systemic exposure of EE and 17-DNE in the presence and absence of dexloxiglumide suggests that dexloxiglumide treatment is unlikely to interfere with the safety and efficacy of oral contraceptives based on the analysis of the resulting pharmacokinetic profile."( Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women.
Abramowitz, W; Jakate, AS; Kapil, R; Patel, A; Persiani, S; Roy, P; Wangsa, J, 2005
)
0.33
"Thirty-day, open-label, fixed-sequence, pharmacokinetic drug-drug interaction study."( Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
Kearney, BP; Mathias, A, 2009
)
0.35
" Geometric mean ratios (90% confidence intervals) for the pharmacokinetic parameters for deacetyl norgestimate and ethinyl estradiol were estimated by using analysis of variance and compared with the no-effect criterion for bioequivalence."( Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
Kearney, BP; Mathias, A, 2009
)
0.35
" This was a 112-day, open-label, fixed-sequence pharmacokinetic (PK) study in healthy female subjects that included a lead-in cycle (OC only; N = 21), cycle 1 (OC only; N = 15), cycle 2 (OC + sofosbuvir; N = 15), and cycle 3 (OC + ledipasvir; N = 15)."( Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects.
German, P; Mathias, A; Moorehead, L; Pang, P; Vimal, M, 2014
)
0.4
" Blood samples for pharmacokinetic analysis were taken until 168 hours postdose."( Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects.
Dutta, S; Foulds, P; King, A; Korb, S; Patel, G; Sumeray, M; Wade, JR, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
" This 2-period crossover study was conducted to evaluate the potential for drug-drug interaction between DMF (240 mg twice daily) and a combined oral contraceptive (OC; norgestimate 250 μg, ethinyl estradiol 35 μg)."( Evaluation of Potential Drug-Drug Interaction Between Delayed-Release Dimethyl Fumarate and a Commonly Used Oral Contraceptive (Norgestimate/Ethinyl Estradiol) in Healthy Women.
Kam, J; Leahy, M; Meka, V; Nestorov, I; Sheikh, SI; Zhao, G; Zhu, B, 2017
)
0.46
" Migraine predominately affects women of childbearing age; thus, it is important to determine potential drug-drug interactions between a common oral contraceptive and drugs used to treat migraine."( A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females.
Eisele, O; Gabriel, K; Lee, E; Mikol, DD; Vutikullird, A; Wang, Y; Xu, Y; Zhou, Y, 2019
)
0.51
"We sought to evaluate potential drug-drug interactions between erenumab and a common oral contraceptive."( A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females.
Eisele, O; Gabriel, K; Lee, E; Mikol, DD; Vutikullird, A; Wang, Y; Xu, Y; Zhou, Y, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"250 mg per 7-day phase, respectively) for 5 days (days 17-21) concurrently with either 200 mg dexloxiglumide (3 times a day on days 17-20, followed by a single dose on day 21) or matching placebo during 2 consecutive 28-day OC dosing cycles."( Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women.
Abramowitz, W; Jakate, AS; Kapil, R; Patel, A; Persiani, S; Roy, P; Wangsa, J, 2005
)
0.33
"Tenofovir DF and norgestimate-ethinyl estradiol are not involved in a clinically significant drug-drug interaction; tenofovir DF did not affect the steady-state pharmacokinetics of norgestimate or ethinyl estradiol, including the concentration at the end of the dosing interval."( Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives.
Kearney, BP; Mathias, A, 2009
)
0.35
"ATV/RTV with dose-normalized EE/NGM resulted in geometric mean reductions of 16% in EE peak plasma concentration (C(max)), 19% in EE area under the concentration-time curve for a dosing interval (AUC([τ])) and 37% in EE lowest plasma concentration (C(min)), compared with EE 35 μg with NGM in the absence of ATV/RTV."( The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women.
Bertz, R; Chung, E; Eley, T; Mahnke, L; Persson, A; Xu, X; Yones, C; Zhang, J, 2011
)
0.37
"25 mg once daily, n = 32) dosing was initiated on days 11 or 8, respectively, with evening (arm 1) or morning (arm 2) dosing; at steady state (days 15 or 22), a single lomitapide dose was administered; CYP3A inhibitor dosing continued for 6 days."( Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects.
Dutta, S; Foulds, P; King, A; Korb, S; Patel, G; Sumeray, M; Wade, JR, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (49)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.04)18.7374
1990's17 (34.69)18.2507
2000's15 (30.61)29.6817
2010's16 (32.65)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 72.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index72.38 (24.57)
Research Supply Index4.47 (2.92)
Research Growth Index5.81 (4.65)
Search Engine Demand Index129.09 (26.88)
Search Engine Supply Index2.13 (0.95)

This Compound (72.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials32 (59.26%)5.53%
Reviews7 (12.96%)6.00%
Case Studies3 (5.56%)4.05%
Observational1 (1.85%)0.25%
Other11 (20.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]